keyword
MENU ▼
Read by QxMD icon Read
search

Pre exposure hiv prophylaxis

keyword
https://www.readbyqxmd.com/read/28329270/hsv-2-acquisition-among-hiv-1-infected-adults-treated-with-tenofovir-as-part-of-combination-antiretroviral-therapy-results-from-the-actg-a5175-pearls-study
#1
Connie Celum, Ting Hong, Anne Cent, Deborah Donnell, Rhoda Morrow, Jared M Baeten, Cynthia Firnhaber, Beatriz Grinsztejn, Mina C Hosseinipour, Umesh Lalloo, Mulinda Nyirenda, Cynthia Riviere, Jorge Sanchez, Breno Santos, Khuanchai Supparatpinyo, James Hakim, N Kumarasamy, Thomas B Campbell
Objective: Tenofovir has in vitro activity against HSV-2 and reduced HSV-2 acquisition as pre-exposure prophylaxis. Whether tenofovir-containing antiretroviral therapy (ART) reduces HSV-2 acquisition is unknown. Design: Secondary analysis of ACTG A5175, a randomized, open-label study of three ART regimens among 1,571 participants. Methods: HSV-2 serostatus was assessed at baseline, exit and prior to ART change. Results: Of 365 HSV-2 seronegative persons, 68 acquired HSV-2 with 24 on tenofovir-containing ART and 44 on ART without tenofovir (HSV-2 incidence 6...
January 30, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28328548/characterization-of-hiv-seroconverters-in-a-tdf-ftc-prep-study-hptn-067-adapt
#2
Mariya V Sivay, Maoji Li, Estelle Piwowar-Manning, Yinfeng Zhang, Sarah E Hudelson, Mark A Marzinke, Rivet K Amico, Andrew Redd, Craig W Hendrix, Peter L Anderson, Kevin Bokoch, Linda Gail-Bekker, Frits van Griensven, Sharon Mannheimer, James P Hughes, Robert Grant, Susan H Eshleman
BACKGROUND: HPTN 067/ADAPT evaluated tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis (PrEP) in women (South Africa) and men who have sex with men (Thailand, US). Participants received once-weekly directly observed TDF/FTC (DOT), and were then randomized to daily, time-driven, or event-driven PrEP. This report describes characterization of 12 HIV seroconversion events in this trial. METHODS: HIV rapid testing was performed at study sites...
March 22, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28322067/the-future-of-pre-exposure-prophylaxis-prep-for-human-immunodeficiency-virus-hiv-infection
#3
Ayşe Elif Özdener, Tae Eun Park, Julie Kalabalik, Rachna Gupta
People at high risk for HIV acquisition should be offered pre-exposure prophylaxis (PrEP). Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is currently the only medication recommended for pre-exposure prophylaxis (PrEP) by the Centers for Disease Control and Prevention (CDC) in people at high risk for HIV transmission. This article will review medications currently under investigation and the future landscape of PrEP therapy. Areas covered: This article will review clinical trials that have investigated nontraditional regimens of TDF/FTC, antiretroviral agents from different drug classes such as integrase strand transfer inhibitors (INSTI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI) as potential PrEP therapies...
March 21, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28291050/medication-sharing-is-rare-among-african-hiv-1-serodiscordant-couples-enrolled-in-an-efficacy-trial-of-oral-pre-exposure-prophylaxis-prep-for-hiv-1-prevention
#4
Kerry A Thomson, Jessica E Haberer, Mark Marzinke, Andrew Mujugira, Craig Hendrix, Connie Celum, Patrick Ndase, Alan Ronald, David R Bangsberg, Jared M Baeten
Sharing of pre-exposure prophylaxis (PrEP) medications is a concern for PrEP implementation. For HIV-1 serodiscordant couples, sharing may undermine HIV-1 prevention benefits and also cause antiretroviral resistance if taken by HIV-1 infected partners. Within a PrEP efficacy trial among HIV-1 serodiscordant couples, we assessed the occurrence of PrEP sharing by self-report and plasma tenofovir concentrations in HIV-1 infected partners. PrEP sharing was self-reported at <0.01% of visits and 0-1.6% of randomly selected and 0% of purposively selected specimens from HIV-1 infected participants had detectable tenofovir concentrations (median: 66...
March 10, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28291047/the-impact-of-pre-exposure-prophylaxis-among-men-who-have-sex-with-men-an-individual-based-model
#5
Parastu Kasaie, Jeff Pennington, Maunank S Shah, Stephen A Berry, Danielle German, Colin P Flynn, Chris Beyrer, David W Dowdy
OBJECTIVES: Pre-exposure prophylaxis (PrEP) is recommended for preventing HIV infection among individuals at high risk, including men who have sex with men (MSM). Although its individual-level efficacy is proven, questions remain regarding population-level impact of PrEP implementation. DESIGN: We developed an agent-based simulation of HIV transmission among MSM, accounting for demographics, sexual contact network, HIV disease stage and use of antiretroviral therapy...
March 10, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28286983/stigma-medical-mistrust-and-perceived-racism-may-affect-prep-awareness-and-uptake-in-black-compared-to-white-gay-and-bisexual-men-in-jackson-mississippi-and-boston-massachusetts
#6
Sean Cahill, S Wade Taylor, Steven A Elsesser, Leandro Mena, DeMarc Hickson, Kenneth H Mayer
Gay and bisexual men and other men who have sex with men (MSM) account for more than two thirds of new HIV infections in the U.S., with Black MSM experiencing the greatest burden. Antiretroviral pre-exposure prophylaxis (PrEP) can reduce MSM's vulnerability to HIV infection. Uptake of PrEP has been limited, particularly among racial and ethnic minority MSM. Four semi-structured focus groups with gay and bisexual men and other MSM at risk for HIV infection were convened in Boston and Jackson in late 2013. The analysis plan utilized a within-case, across-case approach to code and analyze emerging themes, and to compare results across the two cities...
March 12, 2017: AIDS Care
https://www.readbyqxmd.com/read/28279960/pre-exposure-prophylaxis-for-infants-exposed-to-hiv-through-breast-feeding
#7
Philippe Van de Perre, Chipepo Kankasa, Nicolas Nagot, Nicolas Meda, James K Tumwine, Anna Coutsoudis, Thorkild Tylleskär, Hoosen Coovadia
No abstract text is available yet for this article.
March 9, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28276922/science-technology-power-and-sex-prep-and-hiv-positive-gay-men-in-paris
#8
Julien Brisson, Vinh-Kim Nguyen
The pre-exposure prophylaxis (PrEP) drug Truvada is a new HIV prevention technology that is predominantly promoted as relevant to HIV-negative gay men. This paper explores what PrEP represents for HIV-positive gay men living in Paris, based upon data collected through interviews and ethnographic research. While HIV-positive gay men do not directly consume Truvada through PrEP, they nonetheless hold opinions and understandings of this drug, specifically as it relates to their own sexuality. This paper expands the representations and meanings of this new technology in a different light through the voices of gay men living with HIV in Paris...
February 21, 2017: Culture, Health & Sexuality
https://www.readbyqxmd.com/read/28274904/gender-specific-combination-hiv-prevention-for-youth-in-high-burden-settings-the-mp3-youth-observational-pilot-study-protocol
#9
Jasmine Buttolph, Irene Inwani, Kawango Agot, Charles M Cleland, Peter Cherutich, James N Kiarie, Alfred Osoti, Connie L Celum, Jared M Baeten, Ruth Nduati, John Kinuthia, Timothy B Hallett, Ramzi Alsallaq, Ann E Kurth
BACKGROUND: Nearly three decades into the epidemic, sub-Saharan Africa (SSA) remains the region most heavily affected by human immunodeficiency virus (HIV), with nearly 70% of the 34 million people living with HIV globally residing in the region. In SSA, female and male youth (15 to 24 years) are at a disproportionately high risk of HIV infection compared to adults. As such, there is a need to target HIV prevention strategies to youth and to tailor them to a gender-specific context. This protocol describes the process for the multi-staged approach in the design of the MP3 Youth pilot study, a gender-specific, combination, HIV prevention intervention for youth in Kenya...
March 8, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28271718/acceptability-of-microbicidal-vaginal-rings-and-oral-pre-exposure-prophylaxis-for-hiv-prevention-among-female-sex-workers-in-a-high-prevalence-us-city
#10
Sarah M Peitzmeier, Catherine Tomko, Erin Wingo, Anne Sawyer, Susan G Sherman, Nancy Glass, Chris Beyrer, Michele R Decker
Biomedical HIV prevention tools including oral pre-exposure prophylaxis (PrEP) and vaginal microbicidal rings hold unique value for high-risk women who may have limited capacity for condom negotiation, including the key populations of sex workers and drug users. Commercial sex is a PrEP indicator in CDC guidelines, yet little is known about female sex workers' (FSWs) knowledge of and attitudes toward PrEP or the recently developed monthly vaginal microbicide rings. We describe knowledge and attitudes toward PrEP and microbicide rings in a sample of 60 mostly drug-using FSWs in Baltimore, Maryland, a high HIV-prevalence US city...
March 8, 2017: AIDS Care
https://www.readbyqxmd.com/read/28260694/a-case-study-of-chewed-truvada-%C3%A2-for-prep-maintaining-protective-drug-levels-as-measured-by-a-novel-urine-tenofovir-assay
#11
Linden Lalley-Chareczko, Devon Clark, Athena F Zuppa, Ganesh Moorthy, Caitlin Conyngham, Karam Mounzer, Helen Koenig
FTC/TDF (Truvada®) given as pre-exposure prophylaxis (PrEP) successfully blocks HIV when taken once daily prior to potential HIV exposure. A 22 year old male reported difficulty swallowing FTC/TDF for PrEP and subsequently began chewing the FTC/TDF tablets. Monthly urine samples assessed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) indicated tenofovir levels >1000 ng/mL, indicative of protection from HIV acquisition, over a 48 week period. Data from observational studies of HIV positive patients details the successful treatment of HIV using crushed FTC/TDF delivered via feeding and gastronomy tubes while small, randomized trials of healthy volunteers demonstrate bioequivalence between whole and crushed FTC/TDF...
March 6, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28257475/awareness-and-attitudes-of-pre-exposure-prophylaxis-for-hiv-prevention-among-physicians-in-guatemala-implications-for-country-wide-implementation
#12
Ian Ross, Carlos Mejia, Johanna Melendez, Philip A Chan, Amy C Nunn, William Powderly, Katherine Goodenberger, Jingxia Liu, Kenneth H Mayer, Rupa R Patel
INTRODUCTION: HIV continues to be a major health concern with approximately 2.1 million new infections occurring worldwide in 2015. In Central America, Guatemala had the highest incident number of HIV infections (3,700) in 2015. Antiretroviral pre-exposure prophylaxis (PrEP) was recently recommended by the World Health Organization (WHO) as an efficacious intervention to prevent HIV transmission. PrEP implementation efforts are underway in Guatemala and success will require providers that are knowledgeable and willing to prescribe PrEP...
2017: PloS One
https://www.readbyqxmd.com/read/28253024/differences-in-cumulative-exposure-and-adherence-to-tenofovir-in-the-voice-iprex-ole-and-prep-demo-studies-as-determined-via-hair-concentrations
#13
Catherine A Koss, Peter Bacchetti, Sharon L Hillier, Edward Livant, Howard Horng, Nyaradzo Mgodi, Brenda G Mirembe, Kailazarid Gomez Feliciano, Stephanie Horn, Albert Y Liu, David V Glidden, Robert M Grant, Leslie Z Benet, Alexander Louie, Ariane van der Straten, Z Mike Chirenje, Jeanne M Marrazzo, Monica Gandhi
Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) prevented HIV acquisition among men and women in several trials and is broadly recommended. In the VOICE and FEM-PrEP trials, however, TDF/FTC-based PrEP did not prevent HIV acquisition among women in eastern and southern Africa. Tenofovir was detected in plasma, reflecting exposure and adherence in recent days, in fewer than one-third of participants. Drug concentrations in hair, which represent cumulative exposure and adherence over weeks to months, have never previously been examined among women on PrEP...
March 2, 2017: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/28250813/modelling-the-evolution-of-hiv-1-virulence-in-response-to-imperfect-therapy-and-prophylaxis
#14
David R M Smith, Nicole Mideo
Average HIV-1 virulence appears to have evolved in different directions in different host populations since antiretroviral therapy first became available, and models predict that HIV drugs can select for either higher or lower virulence, depending on how treatment is administered. However, HIV virulence evolution in response to "leaky" therapy (treatment that imperfectly suppresses viral replication) and the use of preventive drugs (pre-exposure prophylaxis) has not been explored. Using adaptive dynamics, we show that higher virulence can evolve when antiretroviral therapy is imperfectly effective and that this evolution erodes some of the long-term clinical and epidemiological benefits of HIV treatment...
March 2017: Evolutionary Applications
https://www.readbyqxmd.com/read/28248625/raising-awareness-of-pre-exposure-prophylaxis-prep-among-women-in-new-york-city-community-and-provider-perspectives
#15
Kate L Collier, Lisa G Colarossi, Kim Sanders
This study explored the knowledge, attitudes, and perceived facilitators and barriers to adoption of HIV pre-exposure prophylaxis (PrEP) among black women and Latinas in the Bronx, NY. Data were collected in focus group discussions (FGDs) held separately with staff (n = 21) and black and Latina female clients aged 18 to 50 (n = 23) of four organizations providing health and social services. Participants were also asked to give feedback about four action messages regarding PrEP for a social marketing campaign...
March 2017: Journal of Health Communication
https://www.readbyqxmd.com/read/28240046/-fusion-and-binding-inhibition-key-target-for-hiv-1-treatment-and-pre-exposure-prophylaxis-targets-drug-delivery-and-nanotechnology-approaches
#16
REVIEW
Tanushree Malik, Gaurav Chauhan, Goutam Rath, R S R Murthy, Amit K Goyal
More than 35 million people are living with HIV worldwide with approximately 2.3 million new infections per year. Cascade of events (cell entry, virus replication, assembly and release of newly formed virions) is involved in the HIV-1 transmission process. Every single step offers a potential therapeutic strategy to halt this progression and HIV fusion into the human host cell is one such stage. Controlling the initial event of HIV-1 transmission is the best way to control its dissemination especially when prophylaxis is concerned...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/28238119/use-of-pre-exposure-prophylaxis-prep-in-young-men-who-have-sex-with-men-is-associated-with-race-sexual-risk-behavior-and-peer-network-size
#17
Lisa M Kuhns, Anna L Hotton, John Schneider, Robert Garofalo, Kayo Fujimoto
Pre-exposure prophylaxis (PrEP) is efficacious to prevent HIV infection, however, uptake among young men who have sex with men (YMSM) is relatively low. The purpose of this study was to describe PrEP use and related factors in a representative sample of YMSM in two cities, Chicago and Houston. YMSM, ages 16-29, were recruited via respondent-driven sampling (RDS) from 2014 to 2016. Correlates of PrEP uptake were assessed in weighted multivariable logistic regression models. A total of 12.2% of participants (of 394) reported ever taking PrEP; Black YMSM had the lowest rates of uptake (4...
February 25, 2017: AIDS and Behavior
https://www.readbyqxmd.com/read/28236498/executive-summary-pre-exposure-prophylaxis-for-prevention-of-hiv-infection-in-adults-in-spain-july-2016
#18
Santiago Moreno, Antonio Antela, Felipe García, Julia Del Amo, Vicente Boix, Pep Coll, Claudia Fortuny, Juan L Gómez Sirvent, Félix Gutiérrez, José A Iribarren, Josep M Llibre, Juan C López Bernaldo de Quirós, Juan Emilio Losa, Ana Lozano, Michael Meulbroek, Julián Olalla, Ferran Pujol, Federico Pulido, Manuel Crespo Casal, Juan González García, José López Aldeguer, Jose A Pérez Molina, Daniel Podzamczer Palter, Antonio Rivero Román
Administration of antiretroviral drugs to individuals exposed to, but not infected by, HIV has been shown to reduce the risk of transmission. The efficacy of pre-exposure prophylaxis (PrEP) makes it obligatory to include it in an integral program of prevention of HIV transmission, together with other measures, such as use of the condom, training, counseling, and appropriate treatment of infected individuals. In this document, the AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica [SEIMC]) provides its views on this important subject...
February 21, 2017: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/28225438/levels-of-intracellular-phosphorylated-tenofovir-and-emtricitabine-correlate-with-natural-substrate-concentrations-in-peripheral-blood-mononuclear-cells-of-persons-prescribed-daily-oral-truvadatm-for-hiv-pre-exposure-prophylaxis
#19
Richard E Haaland, Angela Holder, Chou-Pong Pau, Alison Swaims-Kohlmeier, Carolyn Dawson, Dawn K Smith, Tebogo M Segolodi, Michael C Thigpen, Lynn A Paxton, Teresa L Parsons, Craig W Hendrix, Clyde E Hart
No abstract text is available yet for this article.
February 14, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28222118/social-structural-behavioral-and-clinical-factors-influencing-retention-in-pre-exposure-prophylaxis-prep-care-in-mississippi
#20
Trisha Arnold, Lauren Brinkley-Rubinstein, Philip A Chan, Amaya Perez-Brumer, Estefany S Bologna, Laura Beauchamps, Kendra Johnson, Leandro Mena, Amy Nunn
Pre-exposure prophylaxis (PrEP) is a biomedical intervention that can reduce rates of HIV transmission when taken once daily by HIV-negative individuals. Little is understood about PrEP uptake and retention in care among the populations most heavily impacted by the HIV epidemic, particularly among young men who have sex with men (YMSM) in the Deep South. Therefore, this study explored the structural, social, behavioral, and clinical factors that affect PrEP use and retention in care among YMSM in Jackson, Mississippi...
2017: PloS One
keyword
keyword
57314
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"